DNA引物和肽增强免疫在小鼠肿瘤模型中引起强大的新抗原特异性CD8 + T细胞反应和治疗保护。

IF 6.2 2区 医学 Q1 IMMUNOLOGY
Oncoimmunology Pub Date : 2026-12-31 Epub Date: 2026-01-11 DOI:10.1080/2162402X.2025.2606497
Pablo Morgado-Cáceres, Francisca Hofmann-Vega, Diego Figueroa, Juan Saavedra-Almarza, Felipe Gálvez-Cancino, Ximena Díaz, Evelyn Menares, Eduardo Roa, Sofia Hidalgo, Manuel Varas-Godoy, Vincenzo Borgna, Alvaro Lladser
{"title":"DNA引物和肽增强免疫在小鼠肿瘤模型中引起强大的新抗原特异性CD8 + T细胞反应和治疗保护。","authors":"Pablo Morgado-Cáceres, Francisca Hofmann-Vega, Diego Figueroa, Juan Saavedra-Almarza, Felipe Gálvez-Cancino, Ximena Díaz, Evelyn Menares, Eduardo Roa, Sofia Hidalgo, Manuel Varas-Godoy, Vincenzo Borgna, Alvaro Lladser","doi":"10.1080/2162402X.2025.2606497","DOIUrl":null,"url":null,"abstract":"<p><p>Therapeutic immunization against tumor neoantigens has the potential to induce potent and highly selective CD8<sup>+</sup> T-cell-mediated antitumor immunity. Consequently, immunization strategies that generate robust neoantigen-specific T-cell responses are needed. Here, we tested homologous and heterologous DNA- and peptide-based immunization strategies using a neoantigen model. We observed that priming with DNA followed by peptide boost immunization elicited the strongest CD8<sup>+</sup> T-cell responses, which exhibited effector and memory precursor phenotypes and led to the formation of circulating and skin-resident memory T cells. In prophylactic settings, this immunization regimen delayed the growth of B16F10 melanoma and rejected EL4 lymphoma cells expressing a self-antigen. In a therapeutic setting, a DNA prime-peptide boost eliminated EL4 tumors expressing the neo-epitope model in most mice. Consistently, DNA prime-peptide boost targeting two bona fide neoepitopes of MC38 tumor model elicited neoepitope-specific CD8<sup>+</sup> T-cell responses and a marked therapeutic effect, which may be enhanced by combining with anti-PD-1 antibody. These results highlight the potential of DNA prime-peptide boost as a promising strategy for therapeutic neoantigen immunization that elicits strong CD8<sup>+</sup> T-cell responses and potent antitumor effects.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"15 1","pages":"2606497"},"PeriodicalIF":6.2000,"publicationDate":"2026-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12802984/pdf/","citationCount":"0","resultStr":"{\"title\":\"DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 <sup>+</sup> T cell responses and therapeutic protection in mouse tumor models.\",\"authors\":\"Pablo Morgado-Cáceres, Francisca Hofmann-Vega, Diego Figueroa, Juan Saavedra-Almarza, Felipe Gálvez-Cancino, Ximena Díaz, Evelyn Menares, Eduardo Roa, Sofia Hidalgo, Manuel Varas-Godoy, Vincenzo Borgna, Alvaro Lladser\",\"doi\":\"10.1080/2162402X.2025.2606497\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Therapeutic immunization against tumor neoantigens has the potential to induce potent and highly selective CD8<sup>+</sup> T-cell-mediated antitumor immunity. Consequently, immunization strategies that generate robust neoantigen-specific T-cell responses are needed. Here, we tested homologous and heterologous DNA- and peptide-based immunization strategies using a neoantigen model. We observed that priming with DNA followed by peptide boost immunization elicited the strongest CD8<sup>+</sup> T-cell responses, which exhibited effector and memory precursor phenotypes and led to the formation of circulating and skin-resident memory T cells. In prophylactic settings, this immunization regimen delayed the growth of B16F10 melanoma and rejected EL4 lymphoma cells expressing a self-antigen. In a therapeutic setting, a DNA prime-peptide boost eliminated EL4 tumors expressing the neo-epitope model in most mice. Consistently, DNA prime-peptide boost targeting two bona fide neoepitopes of MC38 tumor model elicited neoepitope-specific CD8<sup>+</sup> T-cell responses and a marked therapeutic effect, which may be enhanced by combining with anti-PD-1 antibody. These results highlight the potential of DNA prime-peptide boost as a promising strategy for therapeutic neoantigen immunization that elicits strong CD8<sup>+</sup> T-cell responses and potent antitumor effects.</p>\",\"PeriodicalId\":48714,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":\"15 1\",\"pages\":\"2606497\"},\"PeriodicalIF\":6.2000,\"publicationDate\":\"2026-12-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12802984/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402X.2025.2606497\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2026/1/11 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2025.2606497","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

针对肿瘤新抗原的治疗性免疫具有诱导强效和高选择性CD8+ t细胞介导的抗肿瘤免疫的潜力。因此,需要产生强大的新抗原特异性t细胞反应的免疫策略。在这里,我们使用新抗原模型测试了基于同源和异种DNA和肽的免疫策略。我们观察到,DNA启动后的肽增强免疫引发了最强的CD8+ T细胞反应,其表现出效应和记忆前体表型,并导致循环和皮肤驻留记忆T细胞的形成。在预防性的情况下,这种免疫方案延缓了B16F10黑色素瘤的生长,并排斥了表达自身抗原的EL4淋巴瘤细胞。在治疗环境中,DNA引物肽增强消除了大多数小鼠表达新表位模型的EL4肿瘤。同样,针对MC38肿瘤模型的两个真正的新表位的DNA引物肽增强引起了新表位特异性CD8+ t细胞的反应和显著的治疗效果,可能与抗pd -1抗体联合使用会增强这种效果。这些结果突出了DNA启动肽增强作为治疗性新抗原免疫的一种有希望的策略的潜力,这种策略可以引起强烈的CD8+ t细胞反应和有效的抗肿瘤作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 <sup>+</sup> T cell responses and therapeutic protection in mouse tumor models.

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 <sup>+</sup> T cell responses and therapeutic protection in mouse tumor models.

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 <sup>+</sup> T cell responses and therapeutic protection in mouse tumor models.

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.

Therapeutic immunization against tumor neoantigens has the potential to induce potent and highly selective CD8+ T-cell-mediated antitumor immunity. Consequently, immunization strategies that generate robust neoantigen-specific T-cell responses are needed. Here, we tested homologous and heterologous DNA- and peptide-based immunization strategies using a neoantigen model. We observed that priming with DNA followed by peptide boost immunization elicited the strongest CD8+ T-cell responses, which exhibited effector and memory precursor phenotypes and led to the formation of circulating and skin-resident memory T cells. In prophylactic settings, this immunization regimen delayed the growth of B16F10 melanoma and rejected EL4 lymphoma cells expressing a self-antigen. In a therapeutic setting, a DNA prime-peptide boost eliminated EL4 tumors expressing the neo-epitope model in most mice. Consistently, DNA prime-peptide boost targeting two bona fide neoepitopes of MC38 tumor model elicited neoepitope-specific CD8+ T-cell responses and a marked therapeutic effect, which may be enhanced by combining with anti-PD-1 antibody. These results highlight the potential of DNA prime-peptide boost as a promising strategy for therapeutic neoantigen immunization that elicits strong CD8+ T-cell responses and potent antitumor effects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncoimmunology
Oncoimmunology ONCOLOGYIMMUNOLOGY-IMMUNOLOGY
CiteScore
12.50
自引率
2.80%
发文量
276
审稿时长
24 weeks
期刊介绍: OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy. As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology. The journal covers a wide range of topics, including: -Basic and translational studies in immunology of both solid and hematological malignancies -Inflammation, innate and acquired immune responses against cancer -Mechanisms of cancer immunoediting and immune evasion -Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells -Immunological effects of conventional anticancer therapies.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书